Health Trials

ALK Fusion Protein Expression

2

Review clinical trials related to ALK Fusion Protein Expression. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.

Participants needed: 12
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsUpdated: Sep 23, 2025Locations: 1
Eligibility criteria

Histologically or cytologically confirmed diagnosis of stage IV NSCLC (or recurr... [+5]

Known additional malignancy that is progressing or has required active treatment... [+6]

Read more
Status: Not yet recruiting

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

This randomized, active-controlled, multicenter, open-label, Phase II study is designed to evaluate the efficacy and safety of ensatinib compared with Platinum-Based Chemotherapy as adjuvant treatment in ALK fusion positive II-IIIA stage non-small cell lung cancer after surgical resection

Participants needed: 152
Trial details
Phase: Phase 2Age: 18-73Biological sex: AllType: InterventionalSponsor: Sichuan UniversityUpdated: Jan 11, 2022
Eligibility criteria

Surgical resection of histologically confirmed Stage IIA to IIIA NSCLC with nega... [+7]

More than 10 weeks before surgery Other co-existing malignancies or malignancies... [+13]

Read more